Please login to the form below
Alzheimer
This page shows the latest Alzheimer news and features for those working in and with pharma, biotech and healthcare.
New report identifies key issues with NICE’s methods for evaluating Alzheimer’s drugs
Several disease-modifying treatments for use in Alzheimer's disease are at varying stages of development and regulatory approval. ... UK, the Alzheimer’s Society and the National Institute of Health and Care Research.
Latest news
-
New £5m project launched to bring Alzheimer’s blood tests to the NHS
Alzheimer’s Research UK, the Alzheimer’s Society and the National Institute of Health and Care Research have announced a £5m-funded project to make blood tests for Alzheimer’s disease ... The Alzheimer’s Research UK’s 2023 Dementia Attitudes
-
FDA grants fast track designation to AviadoBio’s dementia gene therapy
The FDA’s decision on AVB-101 comes shortly after the Alzheimer's Society raised concerns that not enough people are being diagnosed with young-onset dementia in England. ... A report from NHS England revealed that 34, 412 people in England have been
-
Alzheimer’s Research UK survey highlights dementia knowledge gaps
Alzheimer’s Research UK has published the results of a nationwide survey of public perceptions of dementia in its Dementia Attitudes Monitor. ... Samantha Benham-Hermetz, executive director of policy and communications at Alzheimer’s Research UK,
-
Biogen/Eisai’s Alzheimer’s disease drug shows promise as subcutaneous formulation
Biogen and Eisai’s Alzheimer’s disease drug has shown promise as a subcutaneous (SC) formulation, according to new data presented by Eisai at this year’s Clinical Trials on ... tasks. Eisai also presented an analysis of a small subgroup of patients
-
Alzheimer’s Society raises concerns over undiagnosed young-onset dementia cases
James White, head of national influencing at Alzheimer’s Society, highlighted the importance of quashing the “common misconception” that dementia is a condition for older people. ... Alzheimer’s Society urges more people to know the symptoms of
More from news
Approximately 219 fully matching, plus 436 partially matching documents found.
Latest Intelligence
-
Can the patient pathway provide a route to success?
To illustrate the point, let’s look at the example of Alzheimer’s disease (AD).
-
The 17th World Congress on Controversies in Neurology
This year, the 17th World Congress on Controversies in Neurology (CONy) took place in Dubrovnik, Croatia and focused on genetic, biomedical, pathological and technological pathways of diseases like Alzheimer’s to
-
Congress is in session – how companies are boosting their impact and engagement
A look through the calendar for the next few months shows delegates coming together for conditions ranging from Alzheimer’s through to cardiology and urology, and journeying from Amsterdam to Vancouver
-
A relentless commitment to neuroscience
Alzheimer’s disease, schizophrenia and other neurological and psychiatric disorders.
-
Preparing for a new era in Alzheimer’s disease
By Charlotte Maule. With the potential approval of the first disease-modifying treatment (DMT) for Alzheimer’s disease (AD) on the horizon – and further treatment candidates in development – stakeholders need to ... Organization. Diagnosis of
More from intelligence
Approximately 10 fully matching, plus 47 partially matching documents found.
Latest appointments
-
Hanover Health appoints James Mole as a director
With fifteen years’ experience of working with government, parliament and healthcare charities – including Cancer Research UK, Diabetes UK and the Alzheimer's Society – Butterworth has a proven track record in senior
-
Cognite strengthens team with two new additions
She has demonstrated real drive and talent across a wide range of disease areas including oncology, MS, diabetes and Alzheimer’s, making her ideally suited to help build successful breakthrough science
-
Metrion Biosciences establishes scientific advisory board
The new board will be chaired by Dr Keith McCullagh, Metrion’s non-executive chairman, and its members will include Dr David Reynolds, chief scientific officer at Alzheimer’s Research UK.
-
J&J’s clinical research neuroscience director joins MedAvante
Prior to this, he was medical director, global medical affairs for Janssen's Alzheimer's disease immunotherapy unit from June 2011 to May 2013.
-
Asceneuron appoints chief medical officer
Alzheimer's disease.
More from appointments
Approximately 0 fully matching, plus 24 partially matching documents found.
Latest from PMHub
-
The right measurement frameworks matter for demonstrating treatment efficacy in clinical trials for Alzheimer’s Disease
The right measurement frameworks matter for demonstrating treatment efficacy in clinical trials for Alzheimer’s Disease. ... Alzheimer’s Disease: Key Insights from Two Decades of Clinical Trial Failures.” Journal of Alzheimer’s Disease.
-
Hidden Heroes – Account Manager’s half-marathon for Alzheimer’s Society
Eryn chose to run on behalf of Alzheimer's Society in memory of her grandad, who passed away in 2007. ... In preparation for her run, Eryn said Alzheimer's Society was hugely supportive.
-
Spotting the Signs of Dementia is the First Step to Diagnosis
Common signs of Alzheimer's disease include difficulties with:. Remembering recent conversations or events. ... It is the second most common type of dementia after Alzheimer's disease.
-
In recognition of the Anniversary of Stonewall, Nucleus Global brings attention and awareness to persistent health care inequities experienced by LGBTQIA+
The RISE study includes a research registry created to help ensure the LGBTQIA+ community is represented in Alzheimer’s research.
-
Rare Disease Day – looking to the future with hope
Alzheimer’s disease).
More from PMHub
Approximately 4 fully matching, plus 26 partially matching documents found.
Subscribe to our email news alerts
- Pfizer’s RSV vaccine granted MHRA approval to protect infants and older adults
- Novavax’s updated COVID-19 vaccine granted Emergency Use Listing by WHO
- FDA to investigate risk of T-cell malignancy from CAR-T cell immunotherapies
- Boehringer Ingelheim and IBM announce AI antibody drug discovery partnership
- New blood test to reduce heart attacks and death rates in A&E heart patients
- Clairvoyant commercialisation
No results were found
PMHub
Oncosec
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
